GE HealthCare Technologies Inc.

GE HealthCare makes medical imaging scanners, ultrasound machines, patient monitors, anesthesia equipment and related software, then services that equipment after installation. Its customers are hospitals, health systems and researchers in more than 160 countries. General Electric, which now operates as GE Aerospace, spun it off as a separate company on January 3, 2023. It is based in Chicago and has about 54,000 employees.

In fiscal 2025, which ended December 31, 2025, revenue was $20.6 billion. Equipment and other products brought in 66%, and service work 34%. Imaging is the largest segment at 45% of revenue. It covers CT scanners (which build 3D pictures from X-rays), magnetic resonance (MR), X-ray, breast-cancer screening and molecular imaging, which shows processes inside cells. Advanced Visualization Solutions made up 26%. It is mainly ultrasound, plus imaging that guides heart, blood-vessel and surgical procedures. Patient Care Solutions, which includes patient monitors, ECG heart tests, anesthesia machines and newborn incubators, added 15%. Pharmaceutical Diagnostics, which makes pharmaceutical products used in diagnosis, added 14%.

The United States accounted for 44.5% of fiscal 2025 revenue, China 9.8% and all other countries 45.7%. Service, consumables such as monitoring accessories, and digital tools bring in recurring revenue between equipment purchases. Results have historically been strongest in the fourth quarter, reflecting customer spending patterns.

• In Q3 FY2026 (ended Sep 30, 2026), revenue was $5.51B, up 7.2% from a year earlier, and net income was $615.0M (+37.9%).
• For fiscal 2025, revenue was $20.63B (+4.8% year over year; +4.1% a year from FY2021 to FY2025) with a 10.1% net margin.

• Over FY2021–FY2025: $200.0M in buybacks and $160.0M in dividends.
• At least 2 consecutive annual increases: every fiscal year in the SEC data (FY2023–FY2025) shows an increase; the true streak may be longer.
• Dividends took 3.1% of earnings and 4.3% of free cash flow in the latest fiscal year.
• Shares outstanding changed -0.4% from Jan 31, 2023 to Oct 21, 2026.

Rank among 1514 US companies

Market value at each year end

GE HealthCare Technologies’s market value went from $35.20B at the end of 2023 to $35.97B on Nov 2, 2026, up 2%; since the end of 2025 it is down 4%.

Form 4 filings from 2025-10-29 to 2026-10-29 (25 read): 3 open-market purchases ($805K) and 0 sales ($0.00).

Large shareholders (13G filings)

ETFs with the most weight in GEHC

1. Hospital budgets and payer cost controls. Governments and insurers keep working to slow healthcare spending. Lower payments to hospitals or tighter limits on how often its equipment is used could lead hospitals to delay purchases or demand lower prices.
2. Tough competition and fast-changing technology. Rivals compete on price, service and innovation. New technology, cheaper products or new entrants could make a product line obsolete, forcing GE HealthCare to cut prices or lose market share.
3. Exposure to China and global instability. China supplied 9.8% of fiscal 2025 revenue, and most sales come from outside the US. Geopolitical or economic instability, or government policies favoring local competitors, could hurt international sales.
4. Strict regulation and anti-bribery enforcement. US and foreign regulators tightly control how its devices and pharmaceutical products are approved and marketed. The company says violations of anti-bribery laws have led to sanctions in the past and could again.
5. Supply shortages that can stall production. Shortages of components or raw materials have restricted manufacturing before and could again, delaying deliveries or raising costs. Outages at its own or suppliers' plants could also halt production or service work.
6. Large debt and pension obligations. As of September 30, 2026, total debt was $9.97 billion against $3.2 billion of cash and investments. The company also carries large pension and retiree healthcare obligations whose costs could exceed estimates.

• Oct 28, 2026 Quarterly results released; Executive or board change
• Sep 22, 2026 Executive or board change; Investor presentation or announcement
• Aug 18, 2026 Executive or board change
• Jul 29, 2026 Investor presentation or announcement
• Jul 29, 2026 Quarterly results released
• Jul 23, 2026 Quarterly results released; Executive or board change
• May 11, 2026 Shareholder vote results; Other company announcement
• Apr 29, 2026 Quarterly results released
• Mar 17, 2026 Executive or board change; Investor presentation or announcement
• Feb 27, 2026 Major agreement signed; Major agreement ended; New debt or financial obligation

GE HealthCare pays a dividend, but a small one. Dividends per share rose from $0.12 in fiscal 2023, the year it split from General Electric, to $0.125 in 2024 and $0.14 in 2025. The 2025 payout used 3.1% of earnings and 4.3% of free cash flow (the cash left after running the business and paying for equipment). The yield was 0.21% as of October 28, 2026. That means income investors would get little cash, and most of any return would need to come from share-price gains. Share repurchases started in fiscal 2025 at $200 million. The share count fell only 0.4% from January 2023 to October 2026.

The shares began trading in January 2023, so they have no record through the 2008, 2020 or 2022 market downturns. The deepest peak-to-trough fall since then was 37.4%, as of October 28, 2026. Single stocks carry more risk than diversified funds, because one company's setbacks can hit the whole investment.